ResMed (RMD) Tops Q3 EPS by 8c, Beats on Revenues

ResMed (NYSE: RMD) reported Q3 EPS of $0.92, $0.08 better than the analyst estimate of $0.84. Revenue for the quarter came in at $591.6 million versus the consensus estimate of $573.95 million.

• Revenue increased 15% to $591.6 million; up 10% on a constant currency basis
• Net income increased by 25%; non-GAAP net income up 32%
• GAAP diluted earnings per share of $0.76; non-GAAP diluted earnings per share of $0.92
• Operating cash flow of $149.1 million in the third quarter

For earnings history and earnings-related data on ResMed (RMD) click here.

You May Also Be Interested In

• FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance
• This digital health stock is ready to re-rate higher: Goldman